| Entry |
|
|---|
| Name |
Polatuzumab vedotin (USAN);
Polatuzumab vedotin (genetical recombination) (JAN);
Polatuzumab vedotin-piiq;
Polivy (TN) |
|---|
| Product |
|
|---|
| Formula |
C6670H10317N1745O2087S40
|
|---|
| Exact mass |
149533.3646
|
|---|
| Mol weight |
149625.3253
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic |
|---|
| Disease |
|
|---|
| Comment |
Antibody-drug conjugate
See Vedotin [DR: D09691]
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC37 Polatuzumab vedotin
D10761 Polatuzumab vedotin (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Polatuzumab Vedotin
D10761 Polatuzumab vedotin (USAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD79B
D10761 Polatuzumab vedotin (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10761
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10761
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10761
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
